There are two ways to finance a micro-cap company. The first is to have a profitable business that generates cash flow. The second, more popular method, is to borrow money from your CEO at a 3x multiple, sell toxic convertible debt to Yorkville Advisors, or merge with a Dogecoin shell company. This week, we saw a masterclass in the latter. If you want to know what the bottom of the capital stack looks like when the lights start flickering, here are the week's most instructive SEC filings.
ABCP (AmBase Corp): The Skyscraper Lawsuit Stub
AmBase isn't really a company; it's a lawsuit wearing a ticker symbol. Its entire existence hinges on a derivative dispute over the 111 West 57th Street property in Manhattan. Last week, it filed a going concern warning and announced it borrowed another $1 million from its Chairman and CEO, Richard Bianco, to pay the lawyers. This supplements a $6 million facility from March. The catch? Bianco's litigation funding comes with return multiples that scale up to 2.8x.
What happened next: The market largely ignored it, valuing the equity at barely over $22 million. If AmBase loses the lawsuit, the equity is a zero. If they win, the first millions off the top go to the CEO at a massive premium, severely diluting the equity upside. It is a zero-sum game where the insider is holding the senior ticket.
TBH (House of Doge Inc.): Much Audit, Very Weakness
Brag House Holdings did a reverse merger with "House of Doge," the official corporate arm of the Dogecoin Foundation, debuting under the TBH ticker. Naturally, they dismissed their auditor (CBIZ) last week and hired a new one (Davidson & Company). The 8-K reads like a checklist of accounting nightmares: multiple material weaknesses spanning cash disbursements, complex debt/equity accounting, and a prior-year going concern warning. To add to the chaos, a board member on the audit committee resigned shortly before this filing.
What happened next: Despite announcing a strategic partnership with MoonPay and inexplicably buying a sponsorship stake in a Swiss professional hockey team, TBH shares are struggling. When your core business model is a meme coin and you cannot reconcile your general ledger, the market tends to lose its sense of humor.
AMS (American Shared Hospital Services): The Bank Takes the Wheel
When you default on your credit agreement, your bank becomes your boss. AMS entered into a forbearance agreement with Fifth Third Bank following a string of blown covenants and a missed April maturity on a $17.3 million term loan. The bank graciously agreed to hold off on liquidating them until June 2027. In exchange, AMS is barred from drawing new revolving debt, must sweep any excess cash over $5 million to the bank, and is mandated to run a sale process for its assets.
What happened next: To survive the squeeze, AMS borrowed $2 million at 10% from its Executive Chairman, throwing in 220,000 warrants at $1.45 just to make it palatable. The stock sits around $1.46 to $1.54,, exactly where you'd expect for an equity tranche that is currently serving as a buffer for Fifth Third's recovery.
WETH (Wetouch Technology Inc.): The Insider Buyout
Wetouch, a touchscreen manufacturer, announced it is selling 31 million shares directly to its controlling shareholders (Qixun and Qihong Technology) at $1.25 per share. That brings in $38.8 million in gross proceeds. The company claims this was priced at a "premium to market" under Nasdaq rules and is locking the shares up for a year.
What happened next: A $38.8 million equity injection sounds great until you realize it is coming from the people who already control the company, effectively cramming down the minority float. The proceeds are allegedly earmarked for in-house development or acquisitions, but when the controlling block buys 31 million shares of a micro-cap in one swing, minority holders are just passengers on someone else's boat.
NWBO (Northwest Biotherapeutics): Yorkville Enters the Chat
If you are a distressed biotech, a standby equity agreement with Yorkville Advisors is a rite of passage. Northwest Biotherapeutics filed an 8-K detailing a $4.9 million convertible note with Yorkville (featuring a 5% original issue discount and a discounted conversion feature) alongside a $50 million standby equity subscription agreement.
What happened next: NWBO trades on the OTC at around 17 cents with a $262 million market cap. Retail message boards are trying to spin the $50 million facility as a sign of institutional confidence. It is not. It is a death spiral financing mechanism designed to convert debt into equity at a discount and sell it into the bid. When a lender gets the right to subscribe for shares at a floating discount to the market price, the market price usually only goes in one direction.
What to watch: The theme here is distress and the cost of avoiding it. Watch AMS's required asset sale timeline closely—forced liquidations rarely command a premium. For NWBO and ABCP, monitor the pace of dilution. In micro-cap land, survival often means sacrificing the equity holders to appease the secured creditors or the insiders holding the litigation purse strings.